← Back
$ROIV All transactions

Roivant Sciences Ltd.

M

$ Value

$15.0M

Shares

1,306,889

Price

$12

Filed

Apr 1

Insider

Name

Sukhatme Mayukh

Title

President & CIO

CIK

0001750050

Roles

Director Officer

Transaction Details

Transaction Date

2026-03-30

Code

M

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

Footnotes

Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). | On March 30, 2026, the hurdle price applicable to 1,306,889 vested CVARs was satisfied and, accordingly, the CVARs were settled into 58,391 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026. | Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs. | Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. | Award of CVARs is fully vested.

Filing Info

Accession No.

0001635088-26-000033

Form Type

4

Issuer CIK

0001635088

Sukhatme Mayukh's History

Date Ticker Type Value
2026-03-31 ROIV F $5.2M
2026-03-30 ROIV M
2026-03-30 ROIV F $787K
2026-03-30 ROIV M $15.0M

Other Insiders at ROIV (90d)

Insider Bought Sold Last
MOMTAZEE JAMES C 2026-04-17
Fitzgerald Meghan $1.9M 2026-03-26
Oren Ilan 2026-04-17
Torti Frank
President and Vant Chair
2026-03-31
Sukhatme Mayukh
President & CIO
2026-03-31
Gline Matthew
CEO
$8.4M 2026-04-16
Venker Eric
President & Immunovant CEO
$5.9M 2026-04-20
Epperly Melissa B, 2026-04-17
Pulik Richard
CFO
2026-04-20
Humes Jennifer
Chief Accounting Officer
$384K 2026-04-20